ArticleFrontiers in neurology2025
The impact of impulse control disorders on cognitive decline in
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuropsychological aspects of impulse control disorders in Parkinson's disease.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Impulse control disorders (ICDs) are common neuropsychiatric symptoms (NPS), which are prevalent among patients with Parkinson's disease (PD). Current research has not clarified the impact of ICDs on cognitive function nor provided sufficient objective evidence. This study aims to explore the effects of ICDs on cognitive functions in PD patients, and further investigate associated cerebral structural changes. Methods: Two hundred PD patients with normal cognition (PDNC) and 69 healthy controls were included from the Parkinson's Progression Markers Initiative (PPMI), among these PDNC, 81 patients with "pure" ICDs (p-ICDs), 69 ICDs combined with other NPS (c-ICDs), and 50 patients without NPS. The cognitive status of each PD patient was obtained every year in four-year follow-up. The difference in conversion rates was obtained by chi-square test. Survival analysis was used to explore the conversion time difference among these groups. Further analysis was conducted on the potential structural difference. Finally, the correlation between significant brain structural changes and neuropsychological assessments were evaluated. Results: The survival analysis suggested that the conversion time of p-ICDs from normal cognition to MCI was significantly delayed compared to NPS-negative, with no significant difference relative to the c-ICDs. There is no significant difference in conversion rates among them. Morphological analysis revealed that compared to the NPS-negative group, the p-ICDs and c-ICDs groups exhibited thickness changes in certain regions (Bonferroni-corrected, Conclusion: Our findings suggest that ICDs might exert a protective effect against cognitive decline, potentially delay the occurrence of MCI in PDNC, which could be associated with alterations in cortical thickness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.